Literature DB >> 1579895

The pregnant antithrombin III deficient patient: management without antithrombin III concentrate.

E Blondel-Hill1, M J Mant.   

Abstract

Pregnant patients with antithrombin III (AT III) deficiency have an unacceptably high risk of venous thromboembolism (VTE). Antithrombotic therapy is therefore recommended. The reported clinical experience of such prophylaxis is limited. Some authors have recommended the use of AT III concentrate in addition to heparin in the management of these patients. We report successful management with heparin alone during pregnancy and the postpartum period in two patients with AT III deficiency. Both patients had experienced VTE during a prior pregnancy; one also experienced VTE during the reported pregnancy. Both patients were therefore at particularly high risk of further VTE. Based on the good results in these two patients, and a review of previously reported cases, we propose that heparin alone, in a dose to maintain the APTT in a therapeutic range, provides adequate prophylaxis and treatment for VTE during pregnancy and delivery in many AT III deficient subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1579895     DOI: 10.1016/0049-3848(92)90239-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

2.  Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency.

Authors:  Andra H James; Barbara A Konkle; Kenneth A Bauer
Journal:  Int J Womens Health       Date:  2013-05-03

3.  Congenital Antithrombin Deficiency in a Pregnant Woman with Right Atrium Thrombosis.

Authors:  Feridoun Sabzi; Donya Khosravi; Reza Faraji
Journal:  Ethiop J Health Sci       Date:  2015-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.